scPharmaceuticals - SCPH Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SCPH shares.
View SCPH analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 12 month price objectives for scPharmaceuticals' shares. Their SCPH share price forecasts range from $13.00 to $25.00. On average, they predict the company's share price to reach $18.00 in the next year. This suggests a possible upside of 222.0% from the stock's current price.
View analysts price targets for SCPH or view top-rated stocks among Wall Street analysts.

scPharmaceuticals' stock was trading at $7.17 at the start of the year. Since then, SCPH shares have decreased by 22.0% and is now trading at $5.59.
View the best growth stocks for 2023 here.

scPharmaceuticals saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,700,000 shares, an increase of 36.0% from the December 31st total of 1,250,000 shares. Based on an average trading volume of 241,900 shares, the days-to-cover ratio is presently 7.0 days. Currently, 8.4% of the shares of the stock are short sold.
View scPharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our SCPH earnings forecast.

scPharmaceuticals Inc. (NASDAQ:SCPH) issued its quarterly earnings data on Wednesday, November, 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.04.

Based on aggregate information from My MarketBeat watchlists, some companies that other scPharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), ImmunoGen (IMGN), VBI Vaccines (VBIV), Selecta Biosciences (SELB), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

(SCPH) raised $96 million in an IPO on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

scPharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

scPharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Thomasville National Bank (0.12%), FNY Investment Advisers LLC (0.08%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include 5Am Partners Iv, Llc, Andrew J Schwab, Jack A Khattar, John H Tucker, Orbimed Advisors Llc and Ra Capital Management, LP.
View institutional ownership trends.

Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SCPH stock can currently be purchased for approximately $5.59.

scPharmaceuticals (NASDAQ:SCPH) has a market capitalization of $153.36 million. The company earns $-28,030,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis.

scPharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The official website for the company is www.scpharma.com. The company can be reached via phone at (617) 517-0730 or via email at tignelzi@scpharma.com.